Kathleen M Carroll1, Brian D Kiluk2, Charla Nich2, Elise E DeVito2, Suzanne Decker3, Donna LaPaglia2, Dianne Duffey2, Theresa A Babuscio2, Samuel A Ball4. 1. Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States. Electronic address: kathleen.carroll@yale.edu. 2. Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States. 3. Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States; New England Mental Illness, Research Education and Clinical Center, VA Connecticut Healthcare System, United States. 4. Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States; The APT Foundation, New Haven Connecticut, 1 Long Wharf, New Haven, CT 06511, United States.
Abstract
BACKGROUND: Selection of an appropriate indictor of treatment response in clinical trials is complex, particularly for the various illicit drugs of abuse. Most widely used indicators have been selected based on expert group recommendation or convention rather than systematic empirical evaluation. Absence of an evidence-based, clinically meaningful index of treatment outcome hinders cross-study evaluations necessary for progress in addiction treatment science. METHOD: Fifteen candidate indicators used in multiple clinical trials as well as some proposed recently are identified and discussed in terms of relative strengths and weaknesses (practicality, cost, verifiability, sensitivity to missing data). Using pooled data from five randomized controlled trials of cocaine dependence (N=434), the indicators were compared in terms of sensitivity to the effects of treatment and relationship to cocaine use and general functioning during follow-up. RESULTS: Commonly used outcome measures (percent negative urine screens; percent days of abstinence) performed relatively well in that they were sensitive to the effects of the therapies evaluated. Others, including complete abstinence and reduction in frequency of use, were less sensitive to effects of specific therapies and were very weakly related to cocaine use or functioning during follow-up. Indicators more strongly related to cocaine use during follow-up were those that reflected achievement of sustained periods of abstinence, particularly at the end of treatment. CONCLUSIONS: These analyses did not demonstrate overwhelming superiority of any single indicator, but did identify several that performed particularly poorly. Candidates for elimination included retention, complete abstinence, and indicators of reduced frequency of cocaine use.
BACKGROUND: Selection of an appropriate indictor of treatment response in clinical trials is complex, particularly for the various illicit drugs of abuse. Most widely used indicators have been selected based on expert group recommendation or convention rather than systematic empirical evaluation. Absence of an evidence-based, clinically meaningful index of treatment outcome hinders cross-study evaluations necessary for progress in addiction treatment science. METHOD: Fifteen candidate indicators used in multiple clinical trials as well as some proposed recently are identified and discussed in terms of relative strengths and weaknesses (practicality, cost, verifiability, sensitivity to missing data). Using pooled data from five randomized controlled trials of cocaine dependence (N=434), the indicators were compared in terms of sensitivity to the effects of treatment and relationship to cocaine use and general functioning during follow-up. RESULTS: Commonly used outcome measures (percent negative urine screens; percent days of abstinence) performed relatively well in that they were sensitive to the effects of the therapies evaluated. Others, including complete abstinence and reduction in frequency of use, were less sensitive to effects of specific therapies and were very weakly related to cocaine use or functioning during follow-up. Indicators more strongly related to cocaine use during follow-up were those that reflected achievement of sustained periods of abstinence, particularly at the end of treatment. CONCLUSIONS: These analyses did not demonstrate overwhelming superiority of any single indicator, but did identify several that performed particularly poorly. Candidates for elimination included retention, complete abstinence, and indicators of reduced frequency of cocaine use.
Authors: J R McKay; A I Alterman; J M Koppenhaver; F D Mulvaney; G B Bovasso; K Ward Journal: Drug Alcohol Depend Date: 2001-03-01 Impact factor: 4.492
Authors: Juned Siddique; C Hendricks Brown; Donald Hedeker; Naihua Duan; Robert D Gibbons; Jeanne Miranda; Philip W Lavori Journal: Psychiatr Ann Date: 2008-12-01
Authors: Jeffrey E Korte; Kathryn M Magruder; Codruta C Chiuzan; Sarah L Logan; Therese Killeen; Dipankar Bandyopadhyay; Kathleen T Brady Journal: Am J Drug Alcohol Abuse Date: 2011-09 Impact factor: 3.829
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Iris M Balodis; Hedy Kober; Patrick D Worhunsky; Michael C Stevens; Godfrey D Pearlson; Kathleen M Carroll; Marc N Potenza Journal: Neuropsychopharmacology Date: 2016-01-21 Impact factor: 7.853
Authors: Sarah W Yip; Elise E DeVito; Hedy Kober; Patrick D Worhunsky; Kathleen M Carroll; Marc N Potenza Journal: Drug Alcohol Depend Date: 2016-07-16 Impact factor: 4.492
Authors: André Q C Miguel; Ayana Jordan; Brian D Kiluk; Charla Nich; Theresa A Babuscio; Jair J Mari; Kathleen M Carroll Journal: J Subst Abuse Treat Date: 2019-08-28
Authors: André Q C Miguel; Brian D Kiluk; Corey R Roos; Theresa A Babuscio; Charla Nich; Jair J Mari; Kathleen M Carroll Journal: J Subst Abuse Treat Date: 2019-09-05
Authors: Sarah W Yip; Iris M Balodis; Kathleen M Carroll; Suchitra Krishnan-Sarin; Marc N Potenza Journal: Drug Alcohol Depend Date: 2016-08-21 Impact factor: 4.492